Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit–harm modelling study

Thomas, 2014, COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care, COPD, 11, 300 Nici, 2020, Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline, Am J Respir Crit Care Med, 201, e56, 10.1164/rccm.202003-0625ST Finney, 2014, Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease, Lancet Respir Med, 2, 919, 10.1016/S2213-2600(14)70169-9 Izquierdo, 2018, The dose of inhaled corticosteroids in patients with COPD: when less is better, Int J Chron Obstruct Pulmon Dis, 13, 3539, 10.2147/COPD.S175047 Bafadhel, 2018, Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials, Lancet Respir Med, 6, 117, 10.1016/S2213-2600(18)30006-7 Suissa, 2013, Inhaled corticosteroids in COPD and the risk of serious pneumonia, Thorax, 68, 1029, 10.1136/thoraxjnl-2012-202872 Rabe, 2020, Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD, N Engl J Med, 383, 35, 10.1056/NEJMoa1916046 Wedzicha, 2017, Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline, Eur Respir J, 49, 50, 10.1183/13993003.00791-2016 Price, 2019, Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study, NPJ Prim Care Respir Med, 29, 38, 10.1038/s41533-019-0150-x Loke, 2011, Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies, Thorax, 66, 699, 10.1136/thx.2011.160028 Gonnelli, 2010, Effect of inhaled glucocorticoids and β(2) agonists on vertebral fracture risk in COPD patients: the EOLO study, Calcif Tissue Int, 87, 137, 10.1007/s00223-010-9392-x Lipson, 2018, Once-daily single-inhaler triple versus dual therapy in patients with COPD, N Engl J Med, 378, 1671, 10.1056/NEJMoa1713901 Ferguson, 2018, Lancet Respir Med, 6, 747, 10.1016/S2213-2600(18)30327-8 Aaron, 2007, Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial, Ann Intern Med, 146, 545, 10.7326/0003-4819-146-8-200704170-00152 Papi, 2018, Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial, Lancet, 391, 1076, 10.1016/S0140-6736(18)30206-X Harries, 2020, Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis, Respir Res, 21, 3, 10.1186/s12931-019-1268-7 Tashkin, 2008, Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial, Drugs, 68, 1975, 10.2165/00003495-200868140-00004 Rennard, 2009, Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial, Drugs, 69, 549, 10.2165/00003495-200969050-00004 Calverley, 2003, Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease, Eur Respir J, 22, 912, 10.1183/09031936.03.00027003 Calverley, 2003, Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial, Lancet, 361, 449, 10.1016/S0140-6736(03)12459-2 Sharafkhaneh, 2012, Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study, Respir Med, 106, 257, 10.1016/j.rmed.2011.07.020 Dekhuijzen, 2016, Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device, Respir Med, 120, 54, 10.1016/j.rmed.2016.09.015 Braeken, 2017, Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom, Int J Chron Obstruct Pulmon Dis, 12, 2425, 10.2147/COPD.S138435 Doucet, 2016, Incidence, prevalence, and mortality trends in chronic obstructive pulmonary disease over 2001 to 2011: a public health point of view of the burden, Can Respir J, 2016, 10.1155/2016/7518287 Yu, 2017, Benefits and harms of roflumilast in moderate to severe COPD Tsung, Physiol Behav, 176, 139 Donaldson, 2003, Longitudinal changes in the nature, severity and frequency of COPD exacerbations, Eur Respir J, 22, 931, 10.1183/09031936.03.00038303 Cazzola, 2008, Outcomes for COPD pharmacological trials: from lung function to biomarkers, Eur Respir J, 31, 416, 10.1183/09031936.00099306 Gail, 1999, Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer, J Natl Cancer Inst, 91, 1829, 10.1093/jnci/91.21.1829 Yebyo, 2019, Finding the balance between benefits and harms when using statins for primary prevention of cardiovascular disease: a modeling study, Ann Intern Med, 170, 1, 10.7326/M18-1279 Siebeling, 2011, Characteristics of Dutch and Swiss primary care COPD patients - baseline data of the ICE COLD ERIC study, Clin Epidemiol, 3, 273, 10.2147/CLEP.S24818 Bertens, 2013, Development and validation of a model to predict the risk of exacerbations in chronic obstructive pulmonary disease, Int J Chron Obstruct Pulmon Dis, 8, 493, 10.2147/COPD.S49609 Arlegui, 2020, Benefit-risk assessment of vaccines. Part II: proposal towards consolidated standards of reporting quantitative benefit-risk models applied to vaccines (BRIVAC), Drug Saf, 43, 1105, 10.1007/s40264-020-00982-9 Pascoe, 2015, Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials, Lancet Respir Med, 3, 435, 10.1016/S2213-2600(15)00106-X Ormaxabal, 1995, The law of diminishing marginal utility in Alfred Marshall's principles of economics, Eur J Hist Econ Thought, 2, 91, 10.1080/10427719500000096 Adibi, 2020, The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study, Lancet Respir Med, 8, 1013, 10.1016/S2213-2600(19)30397-2